Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines, with a price target of $1,201....

H.C. Wainwright Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), BioCryst (BCRX) a...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Privia Health Group (PRV...

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. ($PRAX) announced an update on their ongoing clinical study. Praxis Precision Medicines is running an extension st...

Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play

Goldman Sachs analyst Kevin Strang initiated coverage with a Buy rating on Praxis Precision Medicines on July 17 and set a price target of $447.00....

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$376.38	+2.61%	581.49K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$376.38	+2.6%	581.49K
3
4
5
6

PRAX

Get Praxis Precision Medicines, Inc. Data in Excel

Get Praxis Precision Medicines, Inc. Data in Excel